Resultados: 15

    WHO global air quality guidelines: particulate matter (‎PM2,5 and PM10)‎, ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide

    Clean air is fundamental to health. Compared to 15 years ago, when the previous edition of these guidelines was published, there is now a much stronger body of evidence to show how air pollution affects different aspects of health at even lower concentrations than previously understood. But here’s what...

    Advice on the use of masks in the community, during home care and in health care settings in the context of the novel coronavirus (2019-nCoV) outbreak

    This document provides rapid advice on the use of medical masks in communities, at home and at healthcare facilities in areas that have reported outbreaks caused by the 2019 novel coronavirus (2019-nCoV). It is intended for public health and infection prevention and control (IPC) professionals, healthcar...

    Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases: Interim guidance

    The purpose of this document is to provide interim guidance to laboratories and stakeholders involved in laboratory testing of patients who meet the definition of suspected case of pneumonia associated with a novel coronavirus identified in Wuhan, China....

    Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected Interim guidance 25 January 2020

    This is the first edition of guidance on infection prevention and control (IPC) strategies for use when infection with a novel coronavirus (2019-nCoV) is suspected. It has been adapted from WHO’s Infection prevention and control during health care for probable or confirmed cases of Middle East respirat...

    Home care for patients with suspected novel coronavirus (2019-nCoV) infection presenting with mild symptoms and management of contacts: Interim guidance

    WHO has developed this interim guidance to meet the need for recommendations on safe home care for patients with suspected COVID-19 who present with mild symptoms a and on public health measures related to the management of their contacts. This document was adapted from the interim guidance on Middle Eas...

    Guidelines for malaria vector control

    The Guidelines for malaria vector control provide a “one-stop shop” for all countries and partners working to implement effective malaria vector control measures. They cover the 2 core malaria vector control interventions – ITNs and IRS – as well as supplementary interventions, namely chemical an...

    WHO guidelines on protecting workers from potential risks of manufactured nanomaterials

    The term nanomaterials refers to materials that have at least one dimension (height, width or length) that is smaller than 100 nanometres (10−7 metre), which is about the size of a virus particle. This particular size dimension represents a major characteristic of manufactured nanomaterials (MNMs). The...

    Clinical management of severe acute respiratory infections when novel coronavirus is suspected: What to do and what not to do

    This interim guidance document aims to help clinicians with supportive management of patients who have acute respiratory failure and septic shock as a consequence of severe infection. Because other complications have been seen (renal failure, pericarditis, DIC, as above) clinicians should monitor for the...

    WHO Guidelines for pharmacological management of pandemic Influenza A(H1N1) 2009 and other influenza viruses: part I recommendations

    The purpose of this document is to provide a basis for advice to clinicians on the use of the currently available antivirals for patients presenting with illness due to influenza virus infection, as well their use for chemoprophylaxis. This guidance updates and replaces the recommendations published in A...

    WHO Guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses: part II review of evidence

    This revised guidance is published in two parts. Part II documents the procedures followed in developing this guidance, together with a review of evidence and other new information on the pharmacological agents considered....